The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 30, 2017
Filed:
Aug. 14, 2013
Applicant:
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Inventors:
Kenneth J. Barr, Boston, MA (US);
John K. Maclean, Brookline, MA (US);
Hongjun Zhang, Newton, MA (US);
Richard T. Beresis, Shanghai, CN;
Neville J. Anthony, Northborough, MA (US);
Matthew Daniels, Somerville, MA (US);
Blair T. Lapointe, Brookline, MA (US);
Nunzio Sciammetta, Sudbury, MA (US);
Assignee:
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01); C07D 213/56 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); C07D 231/56 (2006.01); C07D 401/14 (2006.01); C07D 451/02 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/46 (2013.01); C07D 213/56 (2013.01); C07D 231/56 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 451/02 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01);
Abstract
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.